In several lymphoma types the absence or low expression levels of PU.1 are associated with constitutive activation of Nuclear Factor kappa-light-chain-enhancer of activated B-cells (NF-κB), a transcription factors which is both causally connected to lymphoma development and determines poor clinical outcome when aberrantly activated. The gene discussed is NFKB1; the disease is lymphoma.